[{"id":"348b6bee-e334-487c-b8b5-38e99c466308","acronym":"ADELA","url":"https://clinicaltrials.gov/study/NCT06382948","created_at":"2024-04-24T17:32:40.686Z","updated_at":"2024-07-02T16:35:07.380Z","phase":"Phase 3","brief_title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","source_id_and_acronym":"NCT06382948 - ADELA","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-26"},{"id":"abd7c1e1-e507-42de-a1cb-233356ada31d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05015816","created_at":"2021-08-20T14:53:16.509Z","updated_at":"2024-07-02T16:35:26.004Z","phase":"","brief_title":"MoleGazer Development Feasibility Study","source_id_and_acronym":"NCT05015816","lead_sponsor":"Oxford University Hospitals NHS Trust","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A mutation • CDK4 mutation","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CDK4 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/12/2026","study_completion_date":" 02/12/2026","last_update_posted":"2023-12-18"},{"id":"68ced0d1-5116-4b3d-8079-1a15f3e6de8f","acronym":"FAIM","url":"https://clinicaltrials.gov/study/NCT04920708","created_at":"2021-06-11T00:54:37.032Z","updated_at":"2024-07-02T16:35:31.322Z","phase":"Phase 2","brief_title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","source_id_and_acronym":"NCT04920708 - FAIM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation","tags":["HER-2 • ER • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • ipatasertib (RG7440) • Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-10-27"},{"id":"90643e5e-fce7-41f7-ae45-87145173023c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00591500","created_at":"2021-01-18T02:11:20.946Z","updated_at":"2024-07-02T16:35:41.257Z","phase":"","brief_title":"A Model for Genetic Susceptibility: Melanoma","source_id_and_acronym":"NCT00591500","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDK4 mutation","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4082","initiation":"Initiation: 11/01/1999","start_date":" 11/01/1999","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-08-02"},{"id":"4ccc2c43-cf80-4471-8f20-ea4d38f5f9ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01037790","created_at":"2021-01-18T04:04:21.968Z","updated_at":"2024-07-02T16:36:33.413Z","phase":"Phase 2","brief_title":"Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer","source_id_and_acronym":"NCT01037790","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2","pipe":" | ","alterations":" KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation","tags":["HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2021-03-11"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"},{"id":"1c6efed5-6fce-43e0-976e-7a67e62c7ecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00339404","created_at":"2021-01-18T01:10:24.604Z","updated_at":"2024-07-02T16:37:20.363Z","phase":"","brief_title":"Genetic Analysis of Familial Melanoma","source_id_and_acronym":"NCT00339404","lead_sponsor":"National Human Genome Research Institute (NHGRI)","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A negative • CDK4 mutation","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative • CDK4 mutation"],"overall_status":"Completed","enrollment":" Enrollment 3000","initiation":"Initiation: 03/04/1999","start_date":" 03/04/1999","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 03/07/2011","study_completion_date":" 03/07/2011","last_update_posted":"2017-07-02"}]